BR112015001459B1 - Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo - Google Patents

Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo Download PDF

Info

Publication number
BR112015001459B1
BR112015001459B1 BR112015001459-3A BR112015001459A BR112015001459B1 BR 112015001459 B1 BR112015001459 B1 BR 112015001459B1 BR 112015001459 A BR112015001459 A BR 112015001459A BR 112015001459 B1 BR112015001459 B1 BR 112015001459B1
Authority
BR
Brazil
Prior art keywords
amino acid
seq
kit
antibody
acid sequence
Prior art date
Application number
BR112015001459-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015001459A8 (pt
BR112015001459A2 (pt
Inventor
Yaron Hadari
Elizabeth M. Mandel-Bausch
Francis Joseph Carr
Timothy David Jones
Laura Clare Alexandra Perry
Original Assignee
Celldex Therapeutics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48916252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015001459(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celldex Therapeutics, Inc filed Critical Celldex Therapeutics, Inc
Publication of BR112015001459A2 publication Critical patent/BR112015001459A2/pt
Publication of BR112015001459A8 publication Critical patent/BR112015001459A8/pt
Publication of BR112015001459B1 publication Critical patent/BR112015001459B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
BR112015001459-3A 2012-07-25 2013-07-24 Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo BR112015001459B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261675751P 2012-07-25 2012-07-25
US201261675762P 2012-07-25 2012-07-25
US61/675,762 2012-07-25
US61/675,751 2012-07-25
PCT/US2013/051815 WO2014018625A1 (en) 2012-07-25 2013-07-24 Anti-kit antibodies and uses thereof

Publications (3)

Publication Number Publication Date
BR112015001459A2 BR112015001459A2 (pt) 2017-07-04
BR112015001459A8 BR112015001459A8 (pt) 2021-11-03
BR112015001459B1 true BR112015001459B1 (pt) 2023-02-14

Family

ID=48916252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001459-3A BR112015001459B1 (pt) 2012-07-25 2013-07-24 Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo

Country Status (19)

Country Link
US (6) US9334332B2 (enExample)
EP (3) EP4063391A1 (enExample)
JP (5) JP6307075B2 (enExample)
KR (1) KR102268351B1 (enExample)
CN (3) CN110256559B (enExample)
AU (1) AU2013295848B2 (enExample)
BR (1) BR112015001459B1 (enExample)
CA (1) CA2880007C (enExample)
DK (2) DK3381943T3 (enExample)
ES (1) ES2673847T3 (enExample)
IL (1) IL236874B (enExample)
MX (1) MX360620B (enExample)
NZ (2) NZ731881A (enExample)
PH (1) PH12015500113A1 (enExample)
RU (1) RU2681730C2 (enExample)
SG (1) SG11201500489YA (enExample)
TW (1) TWI596113B (enExample)
WO (1) WO2014018625A1 (enExample)
ZA (1) ZA201500457B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
CN110256559B (zh) 2012-07-25 2023-05-26 塞尔德克斯医疗公司 抗kit抗体及其用途
KR20150131173A (ko) 2013-03-15 2015-11-24 노파르티스 아게 항체 약물 접합체
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
WO2016154588A1 (en) 2015-03-25 2016-09-29 Children's Hospital Medical Center Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
CN109661400A (zh) 2016-06-17 2019-04-19 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法
MA45602A (fr) * 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
CN110461876B (zh) 2017-01-20 2024-05-17 海德堡医药研究有限责任公司 用于耗尽cd137+细胞的组合物和方法
JP7129426B2 (ja) 2017-05-12 2022-09-01 ザ ジャクソン ラボラトリー Ｍｈｃクラスｉおよびｍｈｃクラスｉｉを欠損しているｎｓｇマウス
TWI789399B (zh) * 2017-06-22 2023-01-11 財團法人生物技術開發中心 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
GB201802201D0 (en) 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
KR102716514B1 (ko) 2018-10-10 2024-10-15 주식회사 노벨티노빌리티 신규 항-c-KIT 항체
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
USD966445S1 (en) * 2019-02-13 2022-10-11 Global Sports Innovation LTD Sports training device
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
JP2022530438A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗ｃｄ１１７抗体薬物複合体およびその使用
CN114650867A (zh) * 2019-08-30 2022-06-21 齐鲁普吉湾生物治疗公司 抗cd20抗体、抗cd37抗体及它们的混合物
AR119979A1 (es) 2019-09-16 2022-01-26 Opsidio Llc Anticuerpos contra el factor de las células madre y métodos de uso de ellas
KR102772859B1 (ko) * 2019-11-25 2025-02-27 주식회사 노벨티노빌리티 c-kit에 대한 항체 및 이의 용도
EP4216971A4 (en) 2020-09-24 2024-10-02 The Jackson Laboratory HUMANIZED MOUSE MODELS FOR EVALUATING CELLULAR IMMUNOTHERAPY
US11297054B1 (en) * 2020-10-06 2022-04-05 International Business Machines Corporation Authentication system(s) with multiple authentication modes using one-time passwords of increased security
EP4281113A4 (en) * 2021-01-22 2024-11-20 Celldex Therapeutics, Inc. TREATMENT OF CHRONIC PRURIGO
JP2024504706A (ja) * 2021-01-22 2024-02-01 セルデックス セラピューティクス，インコーポレーテッド 抗ｋｉｔ抗体及びその使用
CN118355025A (zh) * 2021-10-07 2024-07-16 新奇贵族公司 肥大细胞相关障碍的治疗

Family Cites Families (322)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050276784A1 (en) 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
JP3213314B2 (ja) 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5545533A (en) 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
NZ246242A (en) 1991-12-02 1996-01-26 Cor Therapeutics Inc Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0548867A2 (en) 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6001803A (en) 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
WO1995002420A2 (en) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5925376C1 (en) 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
US5618709A (en) 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1658772A3 (en) 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5998596A (en) 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
EP0841068B1 (en) 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6127366A (en) 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE321757T1 (de) 1995-12-08 2006-04-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5958769A (en) 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
WO1997027854A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6066738A (en) 1996-01-30 2000-05-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
KR100497017B1 (ko) 1996-03-22 2005-11-29 휴먼 게놈 사이언시즈, 인코포레이티드 고사유도분자ii
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US5648239A (en) 1996-06-21 1997-07-15 Incyte Pharmaceuticals, Inc. Human camp-dependent protein kinase inhibitor homolog
CA2259222A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
SI0956865T2 (sl) 1996-08-12 2011-04-29 Mitsubishi Pharma Corp Zdravila, ki obsegajo inhibitor Rho-kinaze
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6414145B1 (en) 1997-01-29 2002-07-02 Zeneca Limited Imidazolyl compounds as inhibitors of farnesyl-protein tranferase
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
WO1998041090A1 (en) 1997-03-19 1998-09-24 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
AU737092B2 (en) 1997-08-15 2001-08-09 Cephalon, Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
AU9692498A (en) 1997-10-10 1999-05-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Complex of biotinylated viral vector and ligand for targeted gene delivery
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001520222A (ja) 1997-10-22 2001-10-30 ゼネカ・リミテッド イミダゾール誘導体およびファルネシルタンパク質トランスフェラーゼインヒビターとしてのそれらの使用
ATE205195T1 (de) 1997-10-22 2001-09-15 Astrazeneca Ab Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6124465A (en) 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
NZ504013A (en) 1997-11-28 2002-02-01 Lg Chemical Ltd Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
US6054466A (en) 1997-12-04 2000-04-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
EP1058683B1 (en) 1998-02-02 2002-12-04 Lg Chemical Limited Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
JP2002513031A (ja) 1998-04-27 2002-05-08 ワーナー−ランバート・カンパニー ファルネシルトランスフェラーゼ阻害剤としての機能化されたアルキルおよびアルケニル側鎖を有するグリシンアミド誘導体
DE69920897T2 (de) 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
FR2787327B1 (fr) 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6143766A (en) 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
US6576812B1 (en) 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
US6458935B1 (en) 1999-06-23 2002-10-01 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
CA2388343A1 (en) 1999-11-12 2001-05-17 Mark Steven Marshall Methods for inhibiting neurofibromatosis type 1 (nf1)
ATE440111T1 (de) 1999-11-29 2009-09-15 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
US20020010203A1 (en) 1999-12-22 2002-01-24 Ken Lipson Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
US6403581B1 (en) 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20110091428A1 (en) 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk PROCESS FOR PURIFYING ANTIBODY
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6914947B2 (en) 2001-02-28 2005-07-05 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for handling time-drift
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7776612B2 (en) 2001-04-13 2010-08-17 Chugai Seiyaku Kabushiki Kaisha Method of quantifying antigen expression
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7419777B2 (en) 2001-08-21 2008-09-02 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
CN1610696A (zh) * 2001-12-20 2005-04-27 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003102017A2 (en) 2002-06-03 2003-12-11 Centocor, Inc. Anti-relp fusion antibodies, compositions, methods and uses
WO2004002425A2 (en) 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
JP4768439B2 (ja) 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
ZA200506202B (en) 2003-01-31 2006-10-25 Celldex Therapeutics Inc Antibody vaccine conjugates and uses therefor
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
US7303893B1 (en) 2003-08-28 2007-12-04 Takeda San Diego, Inc. Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US7511032B2 (en) 2003-10-22 2009-03-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
AU2004297988A1 (en) 2003-12-04 2005-06-23 Laboratoires Serono Sa Methods for identifying modulators of active KIT tyrosine kinase receptor
NZ548702A (en) 2004-01-09 2009-06-26 Pfizer Antibodies to MAdCAM
AU2005219626B2 (en) 2004-03-01 2010-11-18 Medimmune Limited 11-hydroxy-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
SI1730315T1 (sl) 2004-03-27 2010-02-26 Klein Hanns Georg Polimorfizmi v genu NOD2/CARD15
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
WO2006012688A1 (en) 2004-08-02 2006-02-09 Amrad Operations Pty Ltd A method of treating cancer comprising a vegf-b antagonist
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
RU2007108716A (ru) 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
CA2586909A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
DE602006011300D1 (de) 2005-04-21 2010-02-04 Spirogen Ltd Pyrrolobenzodiazepine
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
EP1885855A4 (en) 2005-05-05 2009-03-04 Valorisation Hsj Soc En Comman CYTOKIN RECEPTOR MODULATORS AND USES THEREOF
US20090136450A1 (en) 2005-08-01 2009-05-28 Ares Trading S.A. Therapy for neurological diseases
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
WO2007039752A1 (en) 2005-10-05 2007-04-12 Spirogen Limited Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
WO2008048671A1 (en) 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
AU2006304876B2 (en) 2005-10-21 2013-04-18 Regents Of The University Of California c-KIT oncogene mutations in melanoma
ES2376083T3 (es) 2005-10-21 2012-03-08 Genzyme Corporation Terapéuticos basados en anticuerpos con actividad adcc mejorada.
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007084949A2 (en) 2006-01-18 2007-07-26 The Uab Research Foundation Modulators of cardiac cell hypertrophy and hyperplasia
KR20080114709A (ko) 2006-02-02 2008-12-31 신타가 비.브이. 수용성 ｃｃ-1065 유사체 및 그들의 결합체
MX2008012728A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP2010500283A (ja) 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
JP2009539403A (ja) * 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
CN101516191A (zh) 2006-09-28 2009-08-26 默克公司 Saha的胺碱盐和其多晶型物
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
EP2076513A1 (en) 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
EP2083830A1 (en) 2006-11-17 2009-08-05 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
US20100143935A1 (en) 2006-12-01 2010-06-10 Apocell, Inc. c-KIT Phosphorylation in Cancer
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
CN101932604A (zh) 2007-03-12 2010-12-29 瓦斯基因治疗公司 EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
CA2682665C (en) 2007-03-27 2015-07-21 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as hsp90 inhibitors
US20110268776A1 (en) 2007-04-25 2011-11-03 Schapira Jay N Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2008150261A1 (en) 2007-06-04 2008-12-11 Wyeth Detection and quantitation of calicheamicin
EA200901646A1 (ru) 2007-06-05 2010-08-30 Йел Юниверсити Ингибиторы рецепторных тирозинкиназ и их применение
US8680293B2 (en) 2007-08-01 2014-03-25 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US20100196923A1 (en) 2007-08-14 2010-08-05 Anthony Atala Pluripotent adult stem cells
US7538395B2 (en) 2007-09-21 2009-05-26 Semiconductor Components Industries, L.L.C. Method of forming low capacitance ESD device and structure therefor
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073139A2 (en) 2007-11-28 2009-06-11 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
EP2615115A3 (en) 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
CN115043946A (zh) 2008-01-03 2022-09-13 斯克里普斯研究院 通过模块识别结构域的抗体靶向
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
WO2009135001A2 (en) 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
US20110182866A1 (en) 2008-05-15 2011-07-28 University Of Miami Isolation of stem cell precursors and expansion in non-adherent conditions
AU2009257487B2 (en) 2008-06-13 2013-01-31 Novartis Ag Substituted benzimidazoles for neurofibromatosis
CN102099038A (zh) 2008-06-27 2011-06-15 印第安纳大学研究与技术公司 用于抑制和/或治疗神经纤维瘤及相关肿瘤的材料和方法
CN102007147B (zh) 2008-06-30 2014-11-05 协和发酵麒麟株式会社 抗cd27抗体
JP2011530535A (ja) 2008-08-07 2011-12-22 セントローズ， エルエルシー グリコシド化合物およびその医薬組成物
CN102224240A (zh) 2008-09-26 2011-10-19 杜克大学 造血干细胞生长因子
JP2012503656A (ja) 2008-09-26 2012-02-09 エウレカ セラピューティクス，インコーポレイテッド 変異体グリコシル化パターンを有する細胞株およびタンパク質
CN102203131A (zh) 2008-10-22 2011-09-28 霍夫曼-拉罗奇有限公司 前列腺干细胞及其用途
JP5677970B2 (ja) 2008-11-03 2015-02-25 シンタルガ・ビーブイ 新規ｃｃ−１０６５類似体およびその複合体
NZ592726A (en) 2008-11-19 2012-12-21 Anthrogenesis Corp Amnion derived adherent cells
US20110281813A1 (en) 2008-12-04 2011-11-17 Cleveland Clinic Method of treating c-kit positive relapsed acute myeloid leukemia
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG175881A1 (en) * 2009-05-12 2011-12-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
BRPI1013177A2 (pt) 2009-05-28 2016-04-12 Glaxo Group Ltd construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
SG10201407129SA (en) 2009-11-06 2014-12-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
CN102724996A (zh) 2009-12-29 2012-10-10 耶鲁大学 血管内皮生长因子(vegf)受体的抑制剂及其使用方法
JP2013517282A (ja) 2010-01-14 2013-05-16 イェール ユニバ−シティ− 受容体チロシンキナーゼ（ｒｔｋ）のインヒビターおよびその使用方法
WO2011119948A1 (en) * 2010-03-26 2011-09-29 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012093172A1 (en) 2011-01-06 2012-07-12 Complix Nv Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
PL2750713T3 (pl) 2011-10-14 2016-03-31 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
CN110256559B (zh) 2012-07-25 2023-05-26 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015112822A1 (en) 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
AU2013295848B2 (en) 2018-05-24
MX2015000999A (es) 2015-11-13
EP4063391A1 (en) 2022-09-28
RU2015106147A (ru) 2016-09-20
EP2877493A1 (en) 2015-06-03
IL236874A0 (en) 2015-03-31
WO2014018625A1 (en) 2014-01-30
EP3381943A1 (en) 2018-10-03
KR102268351B1 (ko) 2021-06-22
US11891452B2 (en) 2024-02-06
BR112015001459A8 (pt) 2021-11-03
JP6875302B2 (ja) 2021-05-19
US20160311924A1 (en) 2016-10-27
US20170158778A1 (en) 2017-06-08
JP6307075B2 (ja) 2018-04-18
JP2018138545A (ja) 2018-09-06
US10781267B2 (en) 2020-09-22
US9605081B2 (en) 2017-03-28
DK3381943T3 (da) 2022-05-16
JP2015531752A (ja) 2015-11-05
TW201408699A (zh) 2014-03-01
KR20150038278A (ko) 2015-04-08
CA2880007A1 (en) 2014-01-30
SG11201500489YA (en) 2015-02-27
HK1211038A1 (en) 2016-05-13
US9334332B2 (en) 2016-05-10
US10184007B2 (en) 2019-01-22
EP2877493B1 (en) 2018-03-21
EP3381943B1 (en) 2022-03-16
US20140065168A1 (en) 2014-03-06
PH12015500113A1 (en) 2015-03-30
CN116574185A (zh) 2023-08-11
AU2013295848A1 (en) 2015-02-05
TWI596113B (zh) 2017-08-21
CA2880007C (en) 2021-12-28
CN110256559A (zh) 2019-09-20
RU2681730C2 (ru) 2019-03-12
BR112015001459A2 (pt) 2017-07-04
ZA201500457B (en) 2021-07-28
US20190106510A1 (en) 2019-04-11
DK2877493T3 (en) 2018-06-14
US20240150493A1 (en) 2024-05-09
US20220010027A1 (en) 2022-01-13
JP2021119779A (ja) 2021-08-19
CN104812775B (zh) 2019-05-03
JP7230095B2 (ja) 2023-02-28
JP2023062063A (ja) 2023-05-02
JP2025060938A (ja) 2025-04-10
CN110256559B (zh) 2023-05-26
NZ630363A (en) 2018-09-28
NZ731881A (en) 2022-07-29
ES2673847T3 (es) 2018-06-26
MX360620B (es) 2018-11-09
IL236874B (en) 2019-08-29
CN104812775A (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
US20240150493A1 (en) Anti-kit antibodies and uses thereof
CA3207070A1 (en) Anti-kit antibodies and uses thereof
KR20250044334A (ko) 항-kit 항체 제형 및 방법
HK1211038B (en) Anti-kit antibodies and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: CONNEMARA MERGER SUB 2 LLC (US)

B25D Requested change of name of applicant approved

Owner name: KOLLTAN, LLC (US)

B25A Requested transfer of rights approved

Owner name: CELLDEX THERAPEUTICS, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/07/2013, OBSERVADAS AS CONDICOES LEGAIS